Zelluna on its clinical momentum as TCR-NK trial advances towards dose escalation

2026-11-06 12:39:00

Zelluna has entered a new phase of development following the initiation of its first-in-human ZIMA-101 trial, with two patients now treated and recruitment progressing on track. Initial safety observations have been encouraging, with no dose-limiting toxicities reported to date, as the company works towards completing its first dose cohort and progressing to higher doses in 2027. BioStock contacted CEO Namir Hassan for a comment.

Read the full interview at biostock.se:

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Read the latest news, keep track of upcoming events, explore BioStock Analytics' in-depth analyses and watch the latest videos! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the Nordic region's leading information channel for life science. Focusing on biotech, medtech, diagnostics and pharmaceutical development, we provide daily news updates, in-depth analyses via BioStock Analytics, exclusive interviews and innovation-driving networking events – all to keep you up to date on developments in the sector.
BioStock – Connecting Innovation & Capital.